Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, recipient of a RMAT designation in the U.S.A. and for which we are in preparation to commence a Phase 3 clinical trial in no option refractory disabling angina.

INVESTMENT HIGHLIGHTS

- CD34+ cell therapy platform company with an advanced clinical pipeline with two programs with cell therapy “breakthrough” designation
- Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12 months based on development milestones across the pipeline
- Strong balance sheet; $33.7 million in cash (June 30, 2019) with no debt and cash runway projected through mid-2020
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience

COMPANY OVERVIEW

Caladrius Biosciences, Inc. | www.caladrius.com

MARKET SNAPSHOT

Ticker Symbol CLBS
Exchange NASDAQ
52-Week Price Range $2.16 - $6.83
Shares Outstanding (6/30) 10.4 million
Cash & Investments (6/30) $33.7 million
Fiscal Year-End December 31

POTENTIAL VALUE CREATING MILESTONES

- YE 2019 Complete enrollment in CLBS12 Phase 2 study
- 1Q 2020 Announce ESCaPE-CMD Phase 2 study topline data
- 1Q 2020 Initiate CLBS14 pivotal Phase 3 study
- 2H 2020 Announce CLBS12 Phase 2 study topline data

C-SUITE LEADERSHIP TEAM

David Mazzo, PhD
President
Chief Executive Officer

Douglas Losordo, MD
Executive Vice President
Global Head of R&D
Chief Medical Officer

Joseph Talamo, CPA, MBA
Senior Vice President
Chief Financial Officer
CD34+ CELL THERAPY PLATFORM

- Naturally occurring vascular repair (endothelial progenitor) cell
- Provokes restorative angiogenesis of the microvasculature
- CD34+ cells re-establish blood flow to under-perfused tissues

CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation.

CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius’ proprietary platform technology selects and delivers a potent, concentrated population of the patient’s own CD34+ cells for optimal therapeutic benefit.

CD34+ CELL THERAPY PIPELINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Development Stage</th>
<th>Commercialization Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLBS14</td>
<td>NORDA</td>
<td>Phase 3 confirmatory (USA; initiation 1Q 2020)</td>
<td>2024</td>
</tr>
<tr>
<td>CLBS12</td>
<td>CLI</td>
<td>Registration eligible Phase 2 (Japan; ongoing)</td>
<td>2021</td>
</tr>
<tr>
<td>CLBS16</td>
<td>CMD</td>
<td>Proof-of-concept (USA; ongoing)</td>
<td>TBD</td>
</tr>
</tbody>
</table>

GCSF mobilization eliminates need for surgical bone marrow aspiration
No genetic manipulation or expansion of cells

Four days or less from donation to treatment
Cost-of-goods an order of magnitude less expensive than CAR-T therapies